All In Biotech

BLA 020522 · Genentech

Nutropin Aq Pen

Somatropin · Injection

Orphan

Last checked: Nov 19, 2026Latest source record: Jul 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Dec 29, 1995

Approved uses

7

Original approval plus efficacy supplements

Registered trials

540

176 Phase 3, 31 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 18, 2005 Supplement 27 · Efficacy LetterLabel
  • Jun 28, 2005 Supplement 21 · Efficacy LetterLabelLabel
  • Apr 13, 2000 Supplement 13 · Efficacy ReviewLabelLetter
  • Dec 1, 1999 Supplement 9 · Efficacy ReviewLetter
  • Dec 17, 1997 Supplement 4 · Efficacy Review
  • Mar 24, 1997 Supplement 2 · Efficacy Review
  • Dec 29, 1995 Original approval · Type 3 - New Dosage Form
6 products under this application
  • NUTROPIN AQ PEN · SOMATROPIN 20MG/2ML (10MG/ML) · INJECTABLE, INJECTION · Discontinued
  • NUTROPIN AQ NUSPIN · SOMATROPIN 20MG/2ML (10MG/ML) · INJECTABLE, INJECTION · Prescription
  • NUTROPIN AQ PEN · SOMATROPIN 10MG/2ML (5MG/ML) · INJECTABLE, INJECTION · Discontinued
  • NUTROPIN AQ NUSPIN · SOMATROPIN 10MG/2ML (5MG/ML) · INJECTABLE, INJECTION · Prescription
  • NUTROPIN AQ NUSPIN · SOMATROPIN 5MG/2ML (2.5MG/ML) · INJECTABLE, INJECTION · Prescription
  • NUTROPIN AQ · SOMATROPIN 10MG/2ML (5MG/ML) · INJECTABLE, INJECTION · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Somatropin" as an intervention, any sponsor and status, largest first.

All 540 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nutropin Aq Nuspin (Somatropin)

2024 spending

$3.9M

Beneficiaries

226

1,340 claims

Per beneficiary

$17,398

$593.14 per unit

View as table
YearSpending
2020$7,670,920
2021$5,129,401
2022$4,648,208
2023$5,651,874
2024$3,931,944

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 80 on PubMed

Sponsor: Roche (Genentech) · Also marketed as Nutropin Aq Nuspin, Nutropin Aq

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.